Clin2
NCT07726147Possibly a fitRecruiting

Testing a new allergy shot for Japanese cedar pollen

Allergen Immunotherapy

Part of Ear, nose & throat, Immune system & allergy, Lungs & breathing clinical trials.

This trial tests a new allergy shot (ITI-9001) for people with Japanese cedar pollen allergy. It aims to see if the shot is safe and can reduce allergy symptoms. The study is for people who have not tried immunotherapy before.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
45 people
Ages
1.5 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old and either male or a woman who cannot become pregnant.
  • You have a confirmed allergy to Japanese cedar pollen (positive skin test and blood test).
  • You have had seasonal eye/nose symptoms from Japanese cedar pollen for at least 2 years, needing medication.
  • You do not have asthma that requires daily medicine (except mild or exercise-induced asthma).
  • You have not had immunotherapy for Japanese cedar pollen before.
  • You are willing to use effective contraception if you are a man with a partner who could become pregnant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04898283Recruiting· Phase 3
Allergy shot study for grass and cypress pollen symptoms

This phase 3 trial tests a specific allergy treatment (an “immunotherapy” shot) for people whose symptoms are triggered by grass and cypress tree pollen. It aims to see if the treatment is safer and more effective at reducing allergy symptoms over time, especially for nose/eye symptoms and some people with asthma.

Valladolid, Castille and León
NCT06846385Recruiting· Phase 2/Phase 3
Testing a new shot for severe seasonal hay fever

This study tests a new injection called MG-K10 for people with moderate-to-severe seasonal hay fever that isn't well controlled by standard treatments like nasal sprays or antihistamines. The goal is to see if it can reduce your allergy symptoms over the pollen season.

Beijing, Beijing Municipality
NCT07701954Recruiting· Phase 1
Testing a new drug for people with allergies and high IgE

This early-phase trial tests a new medication, LCA-0061, in healthy people with high IgE levels (a sign of allergies). Part B specifically includes those with a peanut allergy. The study aims to see how safe the drug is and how the body processes it.

Mississauga, Ontario
NCT07459452Not yet recruiting· Phase 2
New injection for year-round nasal allergies

This study tests a new injection called JYB1904 for people with year-round nasal allergies. It may help reduce symptoms like sneezing, stuffy nose, and runny nose.

NCT07309432Recruiting· Phase 3
Birch allergy shot study for eye symptoms

This trial tests a new antibody treatment for eye allergy symptoms caused by birch pollen. It may help if you have severe eye allergies during birch season.

Andover, Massachusetts
NCT04891237Recruiting· Phase 3
Grass and olive allergy vaccine trial for teens to older adults

This Phase 3 trial tests whether an allergy treatment can reduce symptoms caused by grass and olive pollen. It also checks safety, especially for breathing and allergic reactions, in people with confirmed grass/olive allergy.

Tarancón, Cuenca

Hear when a new Allergen Immunotherapy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.